A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy

BACKGROUND: Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that retains the antitumor effects of trastuzumab while also delivering the cytotoxic antimicrotubule agent, DM1, directly to tumor cells that overexpress human epidermal growth factor receptor 2. The pharmacokinetic (PK) profil...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Medicine (Baltimore)
Päätekijät: Ji, Dongmei, Shen, Weina, Zhang, Jian, Cao, Junning, Li, Wenhua, Lam, Lisa H., Wu, Fan, Wang, Bei, Li, Zao, Sun, Guofang, Hu, Xichun, Chen, Shang-Chiung
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Lippincott Williams & Wilkins 2020
Aiheet:
5750
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7598804/
https://ncbi.nlm.nih.gov/pubmed/33126339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000022886
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
Lataa...

Samankaltaisia teoksia